Marker for statin treatment stratification in heart failure

US11460474B2 · kind B2 · utility

Assignee

• Roche Diagnostics Operations, Inc. · US

Inventors

• Dirk Block · Bichl, DE
• Hanspeter Brunner · Münchenstein, CH
• Thomas Dieterle · Freiburg (Elbe), DE
• Ursula-Henrike Wienhues-Thelen · Krailling, DE
• Christian Zaugg · Rheinfelden, CH
• Andre Ziegler · Läufelfingen, CH

Key dates

• Filing date: Jan 25, 2019
• Grant date: Oct 4, 2022
• Expiry date: Jan 25, 2039

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/52
• WIPO field: Measurement
• WIPO sector: Instruments

Abstract

The present disclosure is directed to a method of identifying a patient having heart failure as likely to respond to a therapy with a statin. The method is based on measuring the level of at least one marker selected from GDF-15 (Growth Differentiation Factor 15), Urea, SHBG (Sex Hormone-Binding Globulin), Uric acid, PLGF (Placental Growth Factor), IL-6 (Interleukin-6), Transferrin, a cardiac Troponin, sFlt-1 (Soluble fms-like tyrosine kinase-1), Prealbumin, Ferritin, Osteopontin, sST2 (soluble ST2), and hsCRP (high sensitivity C-reactive protein) in a sample from a patient. Further envisaged is a method of predicting the risk of a patient to suffer from death or hospitalization, wherein the patient has heart failure and undergoes a therapy with a statin. The method is also based on the measurement of the level of at least one of the aforementioned markers.